{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T01:25:24Z","timestamp":1768267524622,"version":"3.49.0"},"reference-count":31,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2002,3,15]],"date-time":"2002-03-15T00:00:00Z","timestamp":1016150400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2002,3,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>CD23 antigen is a cell surface protein considered important in the differentiation of chronic lymphocytic leukemia (CLL) from other lymphoid leukemias.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>To better clarify CD23 role as a diagnostic tool, the authors retrospectively evaluated clinical and laboratory features of 372 patients who were referred to M.D. Anderson Cancer Center with a diagnosis of CLL or B\u2010cell chronic lymphoproliferative disease.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>Most of the patients (91%) were CD19+\/CD5+. Only 6% of these CD19+\/CD5+ patients were CD23\u2212. Overall, CD23\u2212 patients had the worse prognostic features compared with CD23+ cases, including anemia (<jats:italic>P<\/jats:italic> = 0.03), massive splenomegaly (<jats:italic>P<\/jats:italic> = 0.000), high lactate dehydrogenase (<jats:italic>P<\/jats:italic> = 0.007), high \u03b22\u2010microglobulin (<jats:italic>P<\/jats:italic> = 0.006), older age (<jats:italic>P<\/jats:italic> = 0.001), and male gender (<jats:italic>P<\/jats:italic> = 0.02). Surface immunoglobulin expression was moderate\/strong in 19 (82%) patients, and FMC\u20107 was positive in 22 (96%) patients. None of the 13 patients tested for CD10 expressed the antigen. Based on morphology, of the CD23, 16 (70%) were diagnosed with mantle cell leukemia (MCL) was diagnosed in 16 (70%) CD23\u2212 patients, 3 (13%) with splenic marginal\u2010zone leukemia, 3 (13%) with prolymphocytic leukemia (PLL) or PLL\/CLL, and 1 (4%) with CLL. No cyclin D1 protein expression was noted by Western blot analysis in the one case that showed typical CLL morphology, and this patient did not require therapy. On the whole, the survival rate of CD23\u2212 patients was significantly worse than that of patients with CD23+. In contrast, 15 of 32 (49%) CD19+\/CD5\u2212 patients were CD23\u2212. CD23 negativity in this group was not associated with distinct clinical features or outcome. Eleven (73%) of these patients were classified as having splenic marginal\u2010zone lymphoma and 4 as having follicular lymphoma.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>These data indicate that CD23 negativity is rare in typical B\u2010cell CLL, and CD23 negativity in patients with CD19+\/CD5+ is suggestive of mantle cell leukemia a more aggressive disease with poor response to conventional therapy in which newer chemotherapy regimens such as hyper\u2010CVAD may be more effective. Cancer 2002;94:1721\u201330. \u00a9 2002 American Cancer Society.<\/jats:p><jats:p>DOI 10.1002\/cncr.10401<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.10401","type":"journal-article","created":{"date-parts":[[2002,8,25]],"date-time":"2002-08-25T19:42:44Z","timestamp":1030304564000},"page":"1721-1730","source":"Crossref","is-referenced-by-count":44,"title":["The clinical and diagnostic relevance of CD23 expression in the chronic lymphoproliferative disease"],"prefix":"10.1002","volume":"94","author":[{"given":"Francesco","family":"DiRaimondo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maher","family":"Albitar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Huh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"O'Brien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Montillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Tedeschi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Lerner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosario","family":"Giustolisi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Keating","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2002,3,15]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.42.6.567"},{"key":"e_1_2_5_3_2","first-page":"591","article-title":"CD23 and chronic lymphocytic leukemia","volume":"19","author":"Sarfati M","year":"1993","journal-title":"Blood Cells"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/105.4.451"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1988.tb04203.x"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V78.7.1795.1795"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1989.tb04336.x"},{"key":"e_1_2_5_8_2","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1182\/blood.V82.4.1239.1239","article-title":"Phenotypic markers and BCL\u20101 gene rearrangement in B\u2010cell chronic lymphocytic leukemia: a Cancer and Leukemia Group B study","volume":"82","author":"Newman RA","year":"1993","journal-title":"Blood"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199409051656"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1979.tb00438.x"},{"key":"e_1_2_5_11_2","first-page":"494","article-title":"Mantle cell leukemia?","volume":"93","author":"Neilson JR","year":"1996","journal-title":"Br J Haematol"},{"key":"e_1_2_5_12_2","first-page":"570","article-title":"t(11;14)(q13;q32): chronic lymphocytic leukaemia or mantle cell leukaemia?","volume":"95","author":"Dascalescu C","year":"1996","journal-title":"Br J Haematol"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.5.1361.1361"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.2870050210"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1995.tb05167.x"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-199605000-00009"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19980201)82:3<567::AID-CNCR20>3.0.CO;2-Z"},{"key":"e_1_2_5_18_2","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1182\/blood.V80.1.29.29","article-title":"Response assessment in chronic lymphocytic leukemia after fludarbine plus prednisone: clinical, pathologic, immunophenotypic, and molecular analysis","volume":"80","author":"Robertson LE","year":"1992","journal-title":"Blood"},{"key":"e_1_2_5_19_2","first-page":"1640","article-title":"The immunological profile of B\u2010cell disorders and proposal for a scoring system for the diagnosis of CLL","volume":"8","author":"Matutes E","year":"1994","journal-title":"Leukemia"},{"key":"e_1_2_5_20_2","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1182\/blood.V84.6.1881.1881","article-title":"Role of low\u2010affinity receptor for IgE (CD23) in normal and leukemic B\u2010cell proliferation","volume":"84","author":"Fournier S","year":"1994","journal-title":"Blood"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1995.tb03314.x"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V83.6.1558.1558"},{"key":"e_1_2_5_23_2","first-page":"2140","article-title":"Cytogenetic analysis of B cell chronic lymphoid leukemias classified according to morphologic and immunophenotypic (FAB) criteria","volume":"9","author":"Hernandez JM","year":"1995","journal-title":"Leukemia"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2400818"},{"issue":"1","key":"e_1_2_5_25_2","first-page":"606a","article-title":"The serum \u03b22\u2010microglobulin (\u03b22m) level is more powerful than stage in predicting response and survival in chronic lymphocytic leukemia (CLL)","volume":"86","author":"Keating MJ","year":"1995","journal-title":"Blood"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V69.3.929.929"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1989.tb07674.x"},{"issue":"2","key":"e_1_2_5_28_2","first-page":"S4","article-title":"Prognostic factors in chronic lymphocytic leukemia","volume":"11","author":"Hallek M","year":"1997","journal-title":"Leukemia"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI115717"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.159.6.2678"},{"key":"e_1_2_5_31_2","first-page":"818","article-title":"CD23 expression in transformed small lymphocytic lymphoma\/chronic lymphoid leukemias and blastic transformations of mantle cell lymphoma","volume":"10","author":"Dunphy CH","year":"1997","journal-title":"Mod Pathol"},{"key":"e_1_2_5_32_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.11.3691"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.10401","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.10401","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T12:31:59Z","timestamp":1760272319000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.10401"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,3,15]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2002,3,15]]}},"alternative-id":["10.1002\/cncr.10401"],"URL":"https:\/\/doi.org\/10.1002\/cncr.10401","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,3,15]]}}}